Physician profile
John E Tower
NPI 1558329359
$34,804.58
in general payments reported to CMS, 2019-2025
28 companies · $3,476 in 2025
The $3,476 reported for 2025 was more than what 80% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,939 · 2020: $6,388 · 2021: $6,745 · 2022: $4,246 · 2023: $3,333 · 2024: $2,677 · 2025: $3,476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,855 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,100 · Education: $531.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,854.83 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,100.00 |
| Education | $530.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $20,961.21 | 2019-2025 | Krystexxa, Tavneos, Enbrel |
| Janssen Biotech, INC. | $3,026.14 | 2020-2025 | Simponi Aria, Tremfya, Remicade |
| Abbvie INC. | $2,573.47 | 2019-2025 | Rinvoq |
| Ucb, INC. | $1,876.69 | 2019-2025 | Bimzelx, Cimzia |
| Alexion Pharmaceuticals, INC. | $1,370.07 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $874.29 | 2019-2025 | |
| Horizon Therapeutics Plc | $809.17 | 2019-2023 | Krystexxa |
| Pfizer INC. | $608.47 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $537.11 | 2019-2025 | Orencia |
| Glaxosmithkline, LLC. | $485.22 | 2019-2025 | Benlysta |
| Lilly USA, LLC | $319.61 | 2019-2025 | Taltz, Zepbound |
| Genzyme Corporation | $238.40 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $235.76 | 2023 | Tremfya |
| Genentech USA, INC. | $124.50 | 2019-2025 | Gazyva, Actemra |
| Intrafusion Gp, LLC | $110.35 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $99.00 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $88.01 | 2023-2025 | Saphnelo |
| Pacira Therapeutics, INC. | $76.52 | 2019-2020 | |
| Sandoz INC. | $71.98 | 2023-2025 | Jubbonti, Hyrimoz |
| Aurinia Pharma U.S., INC. | $71.19 | 2023-2025 | Lupkynis |
| Fresenius Kabi USA, LLC | $55.78 | 2024-2025 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.64 | 2023-2024 | Cyltezo |
| Organon LLC | $40.96 | 2023-2025 | Hadlima, Renflexis |
| Sobi, INC | $28.42 | 2021 | |
| Ani Pharmaceuticals, INC. | $26.25 | 2025 | Purified Cortrophin Gel |
| Merck Sharp & Dohme LLC | $15.53 | 2020 | |
| Hikma Pharmaceuticals USA | $14.59 | 2019 | |
| Bioventus LLC | $13.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Tower listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.